EGFR and non-small cell lung carcinoma: The patient would have lost the opportunity to receive gefitinib treatment if had just been diagnosed as having inoperable advanced NSCLC, because the molecular testing guideline does not recommend EGFR mutation analysis in patients with SQC[14].